Ivan R. Gonzalez: Project Orbis: A global initiative to accelerate the review of cancer drugs in the US, Canada, and the UK

Ivan R. Gonzalez, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X:

”Project Orbis: A global initiative to accelerate the review of cancer drugs in the US, Canada, and the UK (2019-2023) reveals:

• 33% of FDA approvals through Orbis.
• Overall survival: 4.1 months (Orbis) vs. 2.7 months (others).
• Reimbursements: 100% (Scotland), 40% (England), 90% (Canada, conditional).
• Access times significantly increased.
• Average monthly cost: $20,000 USD.

Spending on medications surpasses the rate of new cases. It’s crucial to evaluate benefits and costs for a comprehensive global health impact. Project Orbis is expanding, but a deeper understanding of its implications is needed.”

Source: Ivan R. Gonzalez/X